ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research

Rhea-AI Summary

ENvue Medical (NASDAQ: FEED) launched a development and integration program to evaluate its clinically validated NanoVibronix vibration technology for reducing pain and discomfort from indwelling nasogastric (NG) tubes.

The program builds on previously published, peer‑reviewed research showing surface acoustic wave micro‑vibration can reduce friction at the tube–tissue interface. The effort is exploratory and focused on technical feasibility, clinical pathway assessment, and regulatory and quality considerations, and does not represent a commercial product launch or regulatory clearance.

Market Reality Check

Price: $4.02 Vol: Volume 317,778 is 6.37x t...

high vol

$4.02 Last Close

Volume Volume 317,778 is 6.37x the 20-day average of 49,865, indicating elevated interest. high

Technical Price at $2.50, trading below 200-day MA of $2.85 and 50% under 52-week high of $5.00.

Peers on Argus

No peer stocks in the provided sector list showed momentum flags, suggesting tod...

No peer stocks in the provided sector list showed momentum flags, suggesting today’s move is company-specific rather than sector-driven.

Historical Context

2 past events · Latest: Jan 08 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Visibility event	Positive	+11.1%	Nasdaq Opening Bell ceremony highlighting enteral access and pain management focus.
Dec 15	Leadership change	Positive	-5.6%	Appointment of experienced healthcare executive as Chairman to support expansion plans.

Pattern Detected

Recent news showed mixed alignment: a leadership change saw a negative reaction, while a visibility-focused event aligned with a strong gain.

Recent Company History

Over recent weeks, ENvue Medical issued visibility and leadership updates. On Dec 15, 2025, the appointment of a veteran healthcare executive as Chairman coincided with a -5.61% move, indicating a divergence between positive governance news and price. On Jan 8, 2026, the Nasdaq Opening Bell announcement aligned with an 11.11% gain, showing that profile-raising events have recently coincided with upside. Today’s program launch fits a pattern of strategic positioning in enteral care and patient comfort.

Market Pulse Summary

This announcement outlines an exploratory integration of NanoVibronix vibration-based technology to ...

Analysis

This announcement outlines an exploratory integration of NanoVibronix vibration-based technology to improve comfort for patients with indwelling nasogastric tubes, without constituting a commercial launch or regulatory clearance. It builds on previously published, peer-reviewed research suggesting benefits at the tube–tissue interface. Recent history shows ENvue balancing visibility events and leadership changes as it advances non-invasive enteral care. Investors may watch for concrete technical feasibility results, clinical pathway decisions, and any future moves to translate this program into regulated, commercial products.

Key Terms

nasogastric tubes, indwelling, enteral care, surface acoustic wave, +3 more

7 terms

nasogastric tubes medical

"to address pain and discomfort associated with indwelling nasogastric (NG) tubes."

A nasogastric tube is a thin, flexible tube passed through the nose down into the stomach to deliver nutrition, fluids or medicine, or to remove stomach contents. For investors, these devices matter because they are routine, high-volume hospital supplies whose demand and regulatory status affect medical-device makers, hospital operating costs, and supply-chain revenues; think of it as a small delivery hose that enables critical care when a patient cannot eat or swallow.

indwelling medical

"pain and discomfort associated with indwelling nasogastric (NG) tubes."

An indwelling device is a medical tool placed inside the body and left there for an extended period, such as a catheter, implantable pump, or long-term sensor. For investors, indwelling products matter because they create ongoing clinical and regulatory responsibilities—durability, infection risk, and reimbursement rules affect sales, liability, and repeat business, much like a built-in appliance that requires maintenance and long-term support.

enteral care medical

"non-invasive solutions for enteral care across clinical and home care settings"

Enteral care is the medical practice of delivering nutrition, fluids or medications directly into the digestive system through the mouth, stomach or intestines, often using feeding tubes or pumps when a person cannot eat normally. Investors watch enteral care because it drives demand for specialized nutrition formulas, tubes, pumps and related services, affects healthcare spending and reimbursement, and signals steady revenue from chronic or long-term patient needs much like a subscription for essential supplies.

surface acoustic wave medical

"surface acoustic wave micro-vibration technology applied to nasogastric tubes can reduce friction"

A surface acoustic wave is a tiny mechanical vibration that travels along the surface of a solid, like a ripple moving across a pond but at ultrasonic frequencies and microscopic scale. Used in electronic components such as filters, sensors and timing devices, these waves determine how well products handle signals and sensing tasks, so improvements, shortages or cost changes in SAW technology can directly affect a maker’s performance, margins and competitive position.

micro-vibration technology technical

"surface acoustic wave micro-vibration technology applied to nasogastric tubes can reduce"

Micro-vibration technology uses precisely controlled, very small oscillations or pulses to move, sense, or interact with materials and devices at tiny scales — think of it as a phone’s subtle buzz made precise enough to pick up or move microscopic things. It matters to investors because it can enable new product features, improve accuracy or manufacturing yield, reduce costs, and create proprietary advantages that may drive sales, margins, or licensing opportunities.

regulatory clearance regulatory

"does not represent a commercial product launch or regulatory clearance announcement"

Regulatory clearance is official permission from a government agency to market, sell, or use a product or service after it meets required safety, quality, or performance standards. For investors it matters because receiving clearance often unlocks revenue, lowers legal and commercial risk, and can materially change a company’s growth outlook—think of it like a driver’s license that legally allows a product to be driven onto the market.

clinical pathway medical

"focus on technical feasibility, clinical pathway assessment, and regulatory and quality"

A clinical pathway is a standardized plan that lays out the steps of care a patient should receive for a specific condition, much like a recipe or roadmap for clinicians. It matters to investors because pathways shape which treatments are used, how quickly patients recover, and how much hospitals and insurers pay, so they can influence sales, adoption and reimbursement prospects for drugs, devices and medical services.

AI-generated analysis. Not financial advice.

The program will integrate the Company’s clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes

TYLER, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing on the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a new development and integration program leveraging vibration-based technology from its NanoVibronix division to address pain and discomfort associated with indwelling nasogastric (NG) tubes.

Nasogastric tubes are among the most widely used devices in hospital care and are frequently required to remain in place for extended periods. While clinically essential, indwelling NG tubes are commonly associated with nasal and throat discomfort during the dwell phase, an issue for which limited mitigation options currently exist.¹^,²^,³

The newly launched program builds on previously published, peer-reviewed clinical research (link to full publication) demonstrating that surface acoustic wave micro-vibration technology applied to nasogastric tubes can reduce friction at the tube–tissue interface during indwelling use.⁴

Doron Besser, MD, CEO of ENvue Medical, commented, “We believe that this program represents a disciplined platform expansion initiative focused on improving the overall enteral care experience by addressing patient comfort during prolonged NG tube use. While this initiative is exploratory in nature and does not represent a commercial product launch or regulatory clearance announcement, we believe the data will be invaluable for our ongoing commercial efforts of our technology.”

Dr. Besser continued, “Enteral care does not end with accurate placement. This program reflects our strategy of responsibly extending the ENvue Platform to address clinically meaningful aspects of patient experience using validated technology we already own. This initiative aligns with our long-term strategy to expand beyond tube placement accuracy and support end-to-end enteral care, including workflow efficiency and patient experience, while maintaining capital discipline.”

The integration program will focus on technical feasibility, clinical pathway assessment, and regulatory and quality considerations to determine how vibration-based comfort technology could be incorporated into ENvue’s broader enteral ecosystem in the future.

References
1. Prabhakaran S. – Nasoenteric Tube Complications
Scand J Surg . 2012;101(3):147-55.

2. Singer AJ et al. – Pain experienced with Nasogastric Intubation  
Ann Emerg Med 1999 Jun;33(6):652-8

3. StatPearls Publishing. Nasogastric Intubation. U.S. National Library of Medicine / NCBI Bookshelf.

4. Schlager A, Metzger YC, Adler SN. Use of surface acoustic waves to reduce pain and discomfort related to indwelling nasogastric tube. Endoscopy. Published ahead of print 2010. DOI: 10.1055/s-0030-1255801.

About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing on the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
  
  

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com

FAQ

What is ENvue Medical (FEED) announcing on January 9, 2026?

ENvue launched a development and integration program to evaluate NanoVibronix vibration technology for reducing discomfort from indwelling nasogastric tubes.

Does the new ENvue (FEED) program mean a commercial product or regulatory clearance?

No; the company says the initiative is exploratory and does not represent a commercial product launch or regulatory clearance.

What clinical evidence supports ENvue's (FEED) NG tube comfort program?

The program builds on previously published, peer‑reviewed research reporting that surface acoustic wave micro‑vibration can reduce tube–tissue friction and related discomfort.

Which ENvue division provides the vibration technology for the FEED program?

The vibration technology comes from ENvue's NanoVibronix division.

What will ENvue (FEED) evaluate in the NG tube integration program?

The company will assess technical feasibility, clinical pathways, and regulatory and quality considerations for potential integration into its enteral ecosystem.

How does ENvue (FEED) describe the strategic goal of the NG tube comfort program?

ENvue says the program aims to extend the ENvue Platform beyond placement accuracy to improve end‑to‑end enteral care, patient experience, and workflow efficiency while maintaining capital discipline.